Health Trials

Follicular Lymphoma and Marginal Zone Lymphoma

2

Review clinical trials related to Follicular Lymphoma and Marginal Zone Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.

Participants needed: 168
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Beijing Mabworks Biotech Co., Ltd.Updated: Nov 20, 2024Locations: 1
Eligibility criteria

Adult patients, >=18 years of age; [+7]

Evidence of refractory to lenalinomide [+13]

Read more
Status: Recruiting

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).

Participants needed: 53
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Beijing Mabworks Biotech Co., Ltd.Updated: Nov 20, 2024Locations: 1
Eligibility criteria

Adult patients, >=18 years of age; [+7]

Evidence ongoing transformation into aggressive NHL [+13]

Read more